Syncona Limited Autolus commences clinical trial programmes
September 18 2017 - 2:00AM
UK Regulatory
TIDMSYNC
Syncona Limited
Autolus commences clinical trial programmes
18 September 2017
Syncona Ltd ("Syncona"), a leading healthcare company focused on investing in
and building global leaders in life science, today notes that its portfolio
company, Autolus, which is developing and commercialising next-generation
engineered T-cell therapies to combat cancer, has announced the commencement of
three clinical trials in its two lead programmes, AUTO2 and AUTO3.
In its AUTO2 APRIL study in multiple myeloma, Autolus has announced the
initiation and completion of the first dose cohort of its Phase I/II study of
its dual-targeted Chimeric Antigen Receptor (CAR) T cell therapy in patients
with relapsed/refractory multiple myeloma. AUTO2 is the first dual targeting
CAR-T cell therapy in clinical development for the treatment of multiple
myeloma.
Autolus has also initiated its AUTO3 programme with two Phase I/II studies,
AMELIA in pediatric Acute Lymphoblastic Leukaemia and ALEXANDER in adult
Diffuse Large B Cell Lymphoma. AUTO3 is the first dual targeting CAR T cell
therapy to enter clinical studies targeting CD19 and CD22 with
independently-acting CARs.
[ENDS]
Enquiries
Syncona Ltd
Siobhan Weaver
Tel: +44 (0) 20 7611 2031
Tulchan Communications
Martin Robinson
Lisa Jarrett-Kerr
Tel: +44 (0) 207 353 4200
Copies of this press release and other corporate information can be found on
the company website at: www.synconaltd.com
About Syncona:
Syncona is a leading FTSE250 healthcare company focused on investing in and
building global leaders in life science. Our vision is to deliver
transformational treatments to patients in truly innovative areas of healthcare
while generating superior returns for shareholders. Our current investment
portfolio consists of seven high quality companies in life science and a
leading range of fund investments. We seek to partner with the best, brightest
and most ambitious minds in science to build globally competitive businesses.
We are established leaders in gene therapy, cell therapy and advanced
diagnostics, and focus on delivering dramatic efficacy for patients in areas of
high unmet need.
Our market leading funds portfolio seeks to generate superior returns by
investing in long only and alternative investment funds. This represents a
productively deployed evergreen funding base which enables us to take a long
term approach to investing in life sciences as we target the best new
opportunities and support our existing portfolio companies to grow and succeed.
Syncona is aligned with two of the premium charitable funders in UK science,
the Wellcome Trust, original founder of Syncona, and Cancer Research UK, both
of which are significant shareholders in our business. We make a donation of
0.3% of Net Asset Value to a range of charities each year.
About Autolus:
Autolus is a clinical-stage, biopharmaceutical company, focused on the
development and commercialisation of engineered T-cell immunotherapy products
to combat cancer. Building on its advanced cell programming and manufacturing
technologies, Autolus has developed a pipeline of product candidates for the
treatment of both haematological malignancies and solid tumours. For further
information please visit the Company's website at: www.autolus.com
About AUTO2 and the APRIL study:
AUTO2 is a chimeric antigen receptor T cell (CAR-T cell) therapy that targets
both B cell maturation antigen (BCMA) and transmembrane activator and calcium
modulator and cyclophilin ligand interactor (TACI). By targeting TACI in
addition to BCMA on the same cancer cell, more patients may be eligible for
CAR-T treatment and less patients may be at risk of cancer relapse due to loss
of BCMA expression on their cancer. In addition, AUTO2 also carries an RQR8
safety switch which allows the T cells to be removed with a single high dose of
rituximab.
The APRIL Study is a single-arm, open-label, multi-centre, Phase I/II Study
evaluating the safety and clinical activity of AUTO2, a CAR-T Cell Treatment
Targeting BCMA and TACI, in patients with relapsed or refractory multiple
myeloma. In the dose-escalation phase I/II study cohorts of patients will
receive ascending doses of AUTO2 to determine the maximum tolerated dose and
establish a recommended dose. The second part of the study is an expansion
phase where patients will receive AUTO2 to further evaluate the safety,
tolerability and clinical activity at this recommended dose.
Multiple myeloma is a type of blood cancer that affects the plasma cells and is
the second most commonly diagnosed blood cancer, after non-Hodgkin lymphoma.
There are a number of approved therapies to treat the disease but there is
currently no cure.
About AUTO3 and the AMELIA and ALEXANDER studies:
AUTO3 is an autologous T cell product, genetically modified to express two
separate chimeric antigen receptors (CARs) which recognise CD19 and CD22, two
antigens expressed by cancer cells in B cell leukaemia and lymphoma. AUTO3 is
designed to minimize the risk of relapse due to antigen loss, a key mechanism
of resistance shown in single antigen targeting CAR-T therapies.
The AMELIA study is is a single?arm, open-label, multi-centre, phase I/II study
evaluating the safety and clinical activity of AUTO3 in paediatric and young
adult patients with relapsed or refractory B Cell Acute Lymphoblastic Leukaemia
(ALL). The ALEXANDER Study is a Phase I/II, open-label, multi-centre study to
evaluate the safety and efficacy of AUTO3 administered by intravenous infusion
in adult Diffuse Large B Cell Lymphoma (DLBCL) patients. The studies are
dose-escalation phase I/II trials in which cohorts of patients will receive
ascending doses of AUTO3 to determine the maximum tolerated dose and establish
a recommended dose. The second part of the study is an expansion phase where
patients will receive AUTO3 to further evaluate the safety, tolerability and
clinical activity at this recommended dose. In addition to the effects of AUTO3
alone, combination with short-duration use of a checkpoint inhibitor is also
being evaluated in the ALEXANDER Study.
ALL is a cancer of the bone marrow and blood, in which the body makes abnormal
white blood cells (lymphocytes). The disease progresses quickly and is the most
common childhood cancer in the U.S and EU. DLBCL is an aggressive type of
non-Hodgkin lymphoma (NHL) that develops from the B cells in the lymphatic
system. It is a rapidly growing blood cancer, which can occur in lymph nodes or
outside of the lymphatic system, in the brain, bone, breast, skin, thyroid,
gastrointestinal tract, and testes.
About CAR-T therapy:
CAR-T therapy involves re-programming a patient's immune system to kill tumour
cells. T-cells, a type of white blood cell, are extracted from a patient's
blood, manipulated outside the body to incorporate the CAR gene, and then
returned to the patient by infusion. The CAR gene introduces a targeting
mechanism to the T-cells, enabling them to recognise, engage and destroy tumour
cells in a highly specific manner. Clinical trials of CAR T-cells in multiple
myeloma and B-cell malignancies, including non-Hodgkin lymphoma, suggest that
this approach may transform treatment of cancer patients, many of whom have no
other therapeutic options.
END
(END) Dow Jones Newswires
September 18, 2017 02:00 ET (06:00 GMT)
Syncona (LSE:SYNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Syncona (LSE:SYNC)
Historical Stock Chart
From Apr 2023 to Apr 2024